GNU 201
Alternative Names: GNU-201Latest Information Update: 15 Oct 2024
Price :
$50 *
At a glance
- Originator Gnubiotics Sciences
- Class Antineoplastics; Glycopeptides; Immunotherapies
- Mechanism of Action Immunomodulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Oct 2024 Gnubiotics Sciences receives patent allowance for glycopeptide-rich compositions in USA
- 25 Jul 2022 Gnubiotics Sciences withdraws the patent covering its glycopeptides filed to the European Patent Office
- 06 Jul 2022 Gnubiotics Sciences collaborates with University Hospital Zurich for the development of the glycopeptides for the treatment of solid tumours